Antiproliferative Immunosuppressants

Antiproliferative immunosuppressants are drugs that suppress the immune response by blocking the proliferation of lymphocytes after they are activated. In transplantation the group includes the antimetabolites mycophenolate and azathioprine, which interfere with DNA synthesis, and the mTOR inhibitors sirolimus and everolimus, which block a key proliferation-signalling pathway; they are typically used alongside a calcineurin inhibitor and steroid.

Definition

Antiproliferative immunosuppressants are agents that inhibit the clonal expansion of activated lymphocytes, either by blocking purine (DNA) synthesis (mycophenolate, azathioprine) or by inhibiting the mammalian target of rapamycin signalling pathway (sirolimus, everolimus).

Scope

This topic covers the antiproliferative agents used as the second pillar of maintenance immunosuppression: the purine-synthesis antimetabolites (mycophenolate, azathioprine) and the mTOR inhibitors (sirolimus, everolimus). It addresses their distinct mechanisms, their adjunctive role in combination regimens, and their principal toxicities. It is reference material on the drug class, not prescribing guidance.

Core questions

• How does blocking lymphocyte proliferation suppress the alloimmune response?
• How do antimetabolites differ mechanistically from mTOR inhibitors?
• Why are antiproliferative agents used in combination with calcineurin inhibitors rather than alone?
• What characteristic toxicities distinguish these agents?

Key concepts

• Antimetabolites (mycophenolate, azathioprine)
• Inosine monophosphate dehydrogenase inhibition
• mTOR inhibitors (sirolimus, everolimus)
• Lymphocyte clonal expansion blockade
• Myelosuppression and gastrointestinal toxicity
• Combination (adjunctive) immunosuppression

Mechanisms

The antimetabolites act on DNA synthesis: mycophenolic acid selectively inhibits inosine monophosphate dehydrogenase, the rate-limiting enzyme of de novo guanosine-nucleotide synthesis on which proliferating lymphocytes depend, while azathioprine is metabolised to purine analogues that disrupt nucleotide synthesis more broadly. The mTOR inhibitors sirolimus and everolimus bind FK-binding protein-12 and inhibit the mammalian target of rapamycin, blocking the cytokine-driven signal that drives the cell cycle from G1 to S phase. In each case activated lymphocytes are prevented from expanding, complementing the upstream activation blockade produced by calcineurin inhibitors. Class-typical toxicities include myelosuppression and gastrointestinal effects for the antimetabolites and impaired wound healing and metabolic effects for the mTOR inhibitors.

Clinical relevance

Antiproliferative agents are a standard second component of maintenance regimens, allowing the alloimmune response to be suppressed at two points and contributing to lower rejection rates; mTOR inhibitors additionally offer a calcineurin-sparing option. This entry describes the pharmacology of the class for reference and does not provide dosing or individualized treatment advice.

History

Azathioprine was among the earliest maintenance immunosuppressants and, with corticosteroids, formed the standard regimen before the calcineurin-inhibitor era. Mycophenolate mofetil was later introduced and, in trials, reduced acute rejection compared with azathioprine, largely displacing it as the preferred antimetabolite. The mTOR inhibitors sirolimus and everolimus were subsequently added to the toolkit, valued in part for their potential to spare calcineurin-inhibitor exposure.

Seminal works

• halloran-2004

Frequently asked questions

How do antimetabolites differ from mTOR inhibitors?

Antimetabolites such as mycophenolate and azathioprine block the synthesis of DNA building blocks needed for lymphocyte division, whereas mTOR inhibitors such as sirolimus and everolimus block the intracellular signalling pathway that drives cells into the proliferation phase.

Why are these drugs combined with a calcineurin inhibitor?

Calcineurin inhibitors block T-cell activation while antiproliferative agents block the subsequent expansion of activated cells; using both targets two steps of the rejection response and allows lower doses of each drug.